Ranitidine Market Synopsis:
Ranitidine Market Size Was Valued at USD 980 Million in 2023, and is Projected to Reach USD 1,370.89 Million by 2032, Growing at a CAGR of 3.8% From 2024-2032.
The ranitidine market can be defined as the global market of the H2 receptor antagonist medication used for the treatment and prevention of the stomach ulcers, the GERD and other similar diseases. The action of ranitidine is to block acid formation hence does help in treating illnesses arising from excess formation of this substance. It is made in the form of pills, capsules, and syrup and is both prescribed by a doctor and available as an OTC drug depending on a country. In addition, market by formulation types and market by distribution network (retail pharmacy, online, hospital pharmacy) and regional markets form the segmentations.
Another factor which has been dynamic over the last couple of years is the change in the market and consumer trends which include the regulation changes of Ranitidine. Credence has been given to H2-receptor antagonists, especially ranitidine for the management of peptic ulcers, GERD and other diseases related to acid over- secretory state. However, the market was threatened with problems related to safety, most notably after the possible carcinogenic impurities were identified, which resulted in temporary removal of baby milk from the market in several areas. This anti-regulatory sweeping extended to individual consumers and replaced Ranitidine as well as other drugs by other medication products which were deemed safer by the consumers due to regulatory concerns. Nevertheless, the market is gradually coming back to normal as producers modify their cycles, and agencies evaluate the safety of the medicine. Thus, the strategies for the stakeholders will concentrate on rebuilding the customer confidence, guaranteeing the safety of the products, and aiming at the continually expanding market with the cost-efficient and easily accessible treatments of the acid-related disorders. Others relate to its formulation such as new forms of Ranitidine and related delivery systems besides Ranitidine associates with other therapeutically active substances that address the various patients’ requirements and ultimately enhance curative effects.
This is is both a threat and an opportunity as the market finds its footing hence becoming competitive. When it comes to their strategic directions, it is safe to assume that companies will direct their efforts toward the search for new formulations in response to safety issues as well as improving quality management systems; market development, including emerging markets in which the need for affordable drugs is rapidly growing. The regulatory environment shall continue to be an essential factor in shaping the growth of the market since efforts will be continually made to assess and modify the risks inherent in the usage of Ranitidine. Also, efforts at informed consumer marketing and sensitization will be crucial if consumer confidence is to be restored, as to which product to birch to besides creating a distinction between superior quality and possible risks in substitute products. The future trends for the Ranitidine market will also depend on the developments in the a field of drug discovery and development, as well as that there is a ever growing interest in the research into the long term effects of the drug and its best utilization in the practice.
Ranitidine Market Trend Analysis:
Ranitidine Market Dynamics
-
A common drug for heartburn relief, and it is a prescription medication, ranitidine experienced issues in its market in connection with safety problems connected with impurities such as NDMA. Subsequently, various national authorities devote and including the FDA and EMA have suggested the withdrawal of all ranitidine-containing products. This led to a drop in usage since consumers and physicians went in search of medications that they thought were safer thus opting for proton pump inhibitors – PPIs more so due to the safety concerns as raised by the manufacture. Due to these issues related to shortage and safety issues surrounding ranitidine, people changed their preference to more safer newly available Ray Brand.
-
Nonetheless, there is still demand in ranitidine resulting from the emerging markets that have not been able to access the currently developed drugs. These are areas where there is weak or limited penetration by the regulatory authorities or wherever there is limited access to PPIs. It turns out to be cost effective and effective for some patients in the management of acid related disorders. Also, there is a particular audience who have developed the tolerance for ranitidine or who choose the familiar and less expensive drug. There might be some opportunities to initiate safer forms or patients’ needs’ satisfaction within these markets for companies while they deal with such shifts.
Growth in the Ranitidine Market
-
An emerging market segment for ranitidine could be the continually growing number of people suffering from gastrointestinal diseases including heart burns and ulcers. Such conditions are opening up market for proper medicines including the Ranitidine because patients are looking for ways to get rid of discomfort and pains. Given that healthcare consciousness is increasing with special attention being paid to emerging markets, there is an increasing interest in using OTC drugs to promptly address these conditions. This trend creates opportunities for market further development by creating cooperative relationships with retail chains and pharmaceutical companies. these can prove useful in assessing the expanding market opportunities and therefore ranitidine manufacturing companies help to widen the established distribution networks, more so as the digestive diseases are more common in certain parts of the world.
-
The trends of earlier expiry of patents on the branded ranitidine has offered an entry to the generic formulations. It is cheaper than brand name ranitidine which is more preferred especially by populations with lower purchasing power. This extension for generics not only opens up new markets but also offers the possibility to introduce ranitidine in different forms or allied to other products, which could be suitable for pediatric patients or for patients with other diseases. Product differentiation is also communicating that different companies can reach out to different parts of the market by being able to cover different needs of different buyers in order effectively capture a larger portion of the market.
Ranitidine Market Segment Analysis:
Ranitidine Market Segmented on the basis of By Indication, Population Type, Dosage Form, Dosage Strength, Mode of Purchase, End User, Distribution Channel, and Region.
By Indication , Intestinal & Stomach Ulcers segment is expected to dominate the market during the forecast period
-
Intestinal & Stomach Ulcers stomach and intestines treatments are sub-segment that mainly targets stomach ulcers associated with lining and the intestines. These medications work largely by inhibiting stomach acid production or by forming an armor around the ulcer to prevent its further charring. Prescribing the patient acid reducers including proton pump inhibitors PPI and H2 receptor antagonists works by reducing the levels of acid in the stomach allowing the ulcer to heal. Coating agents, however, forms a physical barrier over the ulcer site so that harsh effects of stomach acid cannot wash over it. These treatments are vital for helping to treat the side effects that are accompanied by ulcers including abdominal pain, bloating and nausea. Eradicating the ulcer and relieving those symptoms also increase patients’ quality of life and avert possible consequences such as bleeding or perforation.
-
Unlike other treatments used in managing the symptoms of the ulcer, these treatment regimens also work towards focal ulcer healing by encouraging tissue repair. Time to heal differs according to the degree of the ulcer but normally most of the patients would require medication both oral and topical to heal the sores gradually. The main aim is not only to eradicate the pain, but also to forestall future ulcer formation. Patients with history of ulcers or those with risk factors including long-term use of NSAIDs, and H. pylori otherwise should continue using something to ensure ulcer enduring is maintained and complications averted.
By Distribution Channel, Hospital Pharmacies segment expected to held the largest share
-
Hospital Pharmacies: Hospital pharmacies are capable of stocking almost any medication sample including parenteral formulations and prescription drugs only. Essential in providing patient specific care to the in patient, who are usually admitted to receive, intensive and immediate care for their diseases/ illness. Enteral medications like drips or shots are very operational in hospitalized patients targeting serious symptoms, infections or post-surgery to help the patient regain speedy strength. All these medication are processed in a very clean environment in order to keep patient’s safety and effectiveness. In the same regard, hospital pharmacies offer patient orientated medication management services to attend to the needs of distinct patients. This makes it possible for the interdisciplinary concerted working thus making it possible to effectively prescribe the right medications in the correct dosages and frequency.
-
Out-patients also visit hospital pharmacies to attend to their … needs. It stocks prescription medicines which are compounded in response to individual requirements for health complications or therapeutic plans that require medical monitoring. The people who work at hospital pharmacies are experts in pharmacology and also can explain how to properly use certain medications, what side effects can be expected, and how the medication might interact with other medications. They also act as important patients’ educators they make sure that the patient knows how to take their medication correctly and safely. This level of support is important in the treatment of people with chronic diseases and in avoiding some adverse effects associated with drug therapy in general, and this will lead to improved client status.
Ranitidine Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
-
Consumers in North America have been affected by challenges to the Ranitidine market after its withdrawal from the market in 2020 over the same issue NDMA—a proven carcinogen in humans. This has resulted in a noticeable decrease in prescribing Ranitidine since other treatments became available in the market, like other H2-RA’s, and PPI’s that are considered safer for acid related disorders. Nevertheless, still there remains the stable demand for the alternative medicine for other pharmaceutical designs where Ranitidine was efficiently launched before. The market transfer from Class I to Class II has been gradual in the US and Canada as the market changes in response to regulation and consumers look for safer products.
-
Discontinuation of Ranitidine has not resulted to complete market pull out since it has been substituted by similar brands. Ranitidine still finds some application and specific indications, especially in countries where access to better drugs or where the transition cost is prohibitive is a problem. The market has also shifted its model to ensure that health care products are brought with relative ease and cheaply primarily where populations are comparatively untapped or in a disease management sense in areas where other types of therapy are not feasible. While regulatory authorities persistently observe new data to alter the guidelines on rate of use and duration, Ranitidine has shrunk down as a market and is still in the treatment plan though at a limited level.
Active Key Players in the Ranitidine Market:
- Sanofi
- GENPHARH
- Sandoz International GmbH
- Teva Pharmaceuticals USA Inc
- GlaxoSmithKline plc
- Mylan N.V.
- Par Pharmaceutical, Perrigo Company plc
- Sun Pharmaceuticals Industries Ltd.
- Amneal Pharmaceuticals, LLC.
- Strides Pharma Science Limited
- Dr. Reddy’s Laboratories Ltd.
- Laboratoire Riva.
- Pharmascience Inc.
- Vita Health Products Inc.
- Other Active Players
|
Global Ranitidine Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 980 Million |
|
Forecast Period 2024-32 CAGR: |
3.8% |
Market Size in 2032: |
USD 1,370.89 Million |
|
|
By Indication |
|
|
|
By Population Type |
|
||
|
By Dosage Form |
|
||
|
By Dosage Strength |
|
||
|
By Mode of Purchase |
|
||
|
By End User |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Ranitidine Market by Product
4.1 Ranitidine Market Snapshot and Growth Engine
4.2 Ranitidine Market Overview
4.3 (Instruments
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 (Instruments: Geographic Segmentation Analysis
4.4 Reagents and kits
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Reagents and kits: Geographic Segmentation Analysis
4.5 Consumables
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Consumables: Geographic Segmentation Analysis
Chapter 5: Ranitidine Market by Application
5.1 Ranitidine Market Snapshot and Growth Engine
5.2 Ranitidine Market Overview
5.3 (Clinical Disease Diagnosis
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 (Clinical Disease Diagnosis: Geographic Segmentation Analysis
5.4 Food and Beverage Testing
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Food and Beverage Testing: Geographic Segmentation Analysis
5.5 Pharmaceutical and Biological Drug Testing
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Pharmaceutical and Biological Drug Testing: Geographic Segmentation Analysis
5.6 Environmental Testing
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Environmental Testing: Geographic Segmentation Analysis
5.7 Cosmetics and Personal Care Products Testing
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Cosmetics and Personal Care Products Testing: Geographic Segmentation Analysis
5.8 Research Applications
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Research Applications: Geographic Segmentation Analysis
5.9 Other Applications
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 Other Applications: Geographic Segmentation Analysis
Chapter 6: Ranitidine Market by Method
6.1 Ranitidine Market Snapshot and Growth Engine
6.2 Ranitidine Market Overview
6.3 (Growth-Based Rapid Microbiology Testing
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 (Growth-Based Rapid Microbiology Testing: Geographic Segmentation Analysis
6.4 Cellular Component-Based Rapid Microbiology Testing
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Cellular Component-Based Rapid Microbiology Testing: Geographic Segmentation Analysis
6.5 Nucleic Acid-Based Rapid Microbiology Testing
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Nucleic Acid-Based Rapid Microbiology Testing: Geographic Segmentation Analysis
6.6 Viability-Based Rapid Microbiology Diagnostic Testing
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Viability-Based Rapid Microbiology Diagnostic Testing: Geographic Segmentation Analysis
6.7 Other Rapid Microbiology Testing Methods
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Other Rapid Microbiology Testing Methods: Geographic Segmentation Analysis
Chapter 7: Ranitidine Market by End-User
7.1 Ranitidine Market Snapshot and Growth Engine
7.2 Ranitidine Market Overview
7.3 (Laboratories and Hospitals
7.3.1 Introduction and Market Overview
7.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.3.3 Key Market Trends, Growth Factors and Opportunities
7.3.4 (Laboratories and Hospitals: Geographic Segmentation Analysis
7.4 Food and Beverage Companies
7.4.1 Introduction and Market Overview
7.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.4.3 Key Market Trends, Growth Factors and Opportunities
7.4.4 Food and Beverage Companies: Geographic Segmentation Analysis
7.5 Pharmaceutical and Biotechnology Companies
7.5.1 Introduction and Market Overview
7.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.5.3 Key Market Trends, Growth Factors and Opportunities
7.5.4 Pharmaceutical and Biotechnology Companies: Geographic Segmentation Analysis
7.6 Contract Research Organizations
7.6.1 Introduction and Market Overview
7.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.6.3 Key Market Trends, Growth Factors and Opportunities
7.6.4 Contract Research Organizations: Geographic Segmentation Analysis
7.7 Other End-Users)
7.7.1 Introduction and Market Overview
7.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
7.7.3 Key Market Trends, Growth Factors and Opportunities
7.7.4 Other End-Users): Geographic Segmentation Analysis
Chapter 8: Company Profiles and Competitive Analysis
8.1 Competitive Landscape
8.1.1 Competitive Benchmarking
8.1.2 Ranitidine Market Share by Manufacturer (2023)
8.1.3 Industry BCG Matrix
8.1.4 Heat Map Analysis
8.1.5 Mergers and Acquisitions
8.2 SANOFI
8.2.1 Company Overview
8.2.2 Key Executives
8.2.3 Company Snapshot
8.2.4 Role of the Company in the Market
8.2.5 Sustainability and Social Responsibility
8.2.6 Operating Business Segments
8.2.7 Product Portfolio
8.2.8 Business Performance
8.2.9 Key Strategic Moves and Recent Developments
8.2.10 SWOT Analysis
8.3 GENPHARM
8.4 SANDOZ INTERNATIONAL GMBH
8.5 TEVA PHARMACEUTICALS USA INC
8.6 GLAXOSMITHKLINE PLC
8.7 MYLAN N.V.
8.8 PAR PHARMACEUTICAL
8.9 PERRIGO COMPANY PLC
8.10 SUN PHARMACEUTICALS INDUSTRIES LTD.
8.11 AMNEAL PHARMACEUTICALS LLC.
8.12 STRIDES PHARMA SCIENCE LIMITED
8.13 DR. REDDY’S LABORATORIES LTD.
8.14 LABORATOIRE RIVA.
8.15 PHARMASCIENCE INC. AND VITA HEALTH PRODUCTS INC
8.16 OTHER ACTIVE PLAYERS
Chapter 9: Global Ranitidine Market By Region
9.1 Overview
9.2. North America Ranitidine Market
9.2.1 Key Market Trends, Growth Factors and Opportunities
9.2.2 Top Key Companies
9.2.3 Historic and Forecasted Market Size by Segments
9.2.4 Historic and Forecasted Market Size By Product
9.2.4.1 (Instruments
9.2.4.2 Reagents and kits
9.2.4.3 Consumables
9.2.5 Historic and Forecasted Market Size By Application
9.2.5.1 (Clinical Disease Diagnosis
9.2.5.2 Food and Beverage Testing
9.2.5.3 Pharmaceutical and Biological Drug Testing
9.2.5.4 Environmental Testing
9.2.5.5 Cosmetics and Personal Care Products Testing
9.2.5.6 Research Applications
9.2.5.7 Other Applications
9.2.6 Historic and Forecasted Market Size By Method
9.2.6.1 (Growth-Based Rapid Microbiology Testing
9.2.6.2 Cellular Component-Based Rapid Microbiology Testing
9.2.6.3 Nucleic Acid-Based Rapid Microbiology Testing
9.2.6.4 Viability-Based Rapid Microbiology Diagnostic Testing
9.2.6.5 Other Rapid Microbiology Testing Methods
9.2.7 Historic and Forecasted Market Size By End-User
9.2.7.1 (Laboratories and Hospitals
9.2.7.2 Food and Beverage Companies
9.2.7.3 Pharmaceutical and Biotechnology Companies
9.2.7.4 Contract Research Organizations
9.2.7.5 Other End-Users)
9.2.8 Historic and Forecast Market Size by Country
9.2.8.1 US
9.2.8.2 Canada
9.2.8.3 Mexico
9.3. Eastern Europe Ranitidine Market
9.3.1 Key Market Trends, Growth Factors and Opportunities
9.3.2 Top Key Companies
9.3.3 Historic and Forecasted Market Size by Segments
9.3.4 Historic and Forecasted Market Size By Product
9.3.4.1 (Instruments
9.3.4.2 Reagents and kits
9.3.4.3 Consumables
9.3.5 Historic and Forecasted Market Size By Application
9.3.5.1 (Clinical Disease Diagnosis
9.3.5.2 Food and Beverage Testing
9.3.5.3 Pharmaceutical and Biological Drug Testing
9.3.5.4 Environmental Testing
9.3.5.5 Cosmetics and Personal Care Products Testing
9.3.5.6 Research Applications
9.3.5.7 Other Applications
9.3.6 Historic and Forecasted Market Size By Method
9.3.6.1 (Growth-Based Rapid Microbiology Testing
9.3.6.2 Cellular Component-Based Rapid Microbiology Testing
9.3.6.3 Nucleic Acid-Based Rapid Microbiology Testing
9.3.6.4 Viability-Based Rapid Microbiology Diagnostic Testing
9.3.6.5 Other Rapid Microbiology Testing Methods
9.3.7 Historic and Forecasted Market Size By End-User
9.3.7.1 (Laboratories and Hospitals
9.3.7.2 Food and Beverage Companies
9.3.7.3 Pharmaceutical and Biotechnology Companies
9.3.7.4 Contract Research Organizations
9.3.7.5 Other End-Users)
9.3.8 Historic and Forecast Market Size by Country
9.3.8.1 Russia
9.3.8.2 Bulgaria
9.3.8.3 The Czech Republic
9.3.8.4 Hungary
9.3.8.5 Poland
9.3.8.6 Romania
9.3.8.7 Rest of Eastern Europe
9.4. Western Europe Ranitidine Market
9.4.1 Key Market Trends, Growth Factors and Opportunities
9.4.2 Top Key Companies
9.4.3 Historic and Forecasted Market Size by Segments
9.4.4 Historic and Forecasted Market Size By Product
9.4.4.1 (Instruments
9.4.4.2 Reagents and kits
9.4.4.3 Consumables
9.4.5 Historic and Forecasted Market Size By Application
9.4.5.1 (Clinical Disease Diagnosis
9.4.5.2 Food and Beverage Testing
9.4.5.3 Pharmaceutical and Biological Drug Testing
9.4.5.4 Environmental Testing
9.4.5.5 Cosmetics and Personal Care Products Testing
9.4.5.6 Research Applications
9.4.5.7 Other Applications
9.4.6 Historic and Forecasted Market Size By Method
9.4.6.1 (Growth-Based Rapid Microbiology Testing
9.4.6.2 Cellular Component-Based Rapid Microbiology Testing
9.4.6.3 Nucleic Acid-Based Rapid Microbiology Testing
9.4.6.4 Viability-Based Rapid Microbiology Diagnostic Testing
9.4.6.5 Other Rapid Microbiology Testing Methods
9.4.7 Historic and Forecasted Market Size By End-User
9.4.7.1 (Laboratories and Hospitals
9.4.7.2 Food and Beverage Companies
9.4.7.3 Pharmaceutical and Biotechnology Companies
9.4.7.4 Contract Research Organizations
9.4.7.5 Other End-Users)
9.4.8 Historic and Forecast Market Size by Country
9.4.8.1 Germany
9.4.8.2 UK
9.4.8.3 France
9.4.8.4 The Netherlands
9.4.8.5 Italy
9.4.8.6 Spain
9.4.8.7 Rest of Western Europe
9.5. Asia Pacific Ranitidine Market
9.5.1 Key Market Trends, Growth Factors and Opportunities
9.5.2 Top Key Companies
9.5.3 Historic and Forecasted Market Size by Segments
9.5.4 Historic and Forecasted Market Size By Product
9.5.4.1 (Instruments
9.5.4.2 Reagents and kits
9.5.4.3 Consumables
9.5.5 Historic and Forecasted Market Size By Application
9.5.5.1 (Clinical Disease Diagnosis
9.5.5.2 Food and Beverage Testing
9.5.5.3 Pharmaceutical and Biological Drug Testing
9.5.5.4 Environmental Testing
9.5.5.5 Cosmetics and Personal Care Products Testing
9.5.5.6 Research Applications
9.5.5.7 Other Applications
9.5.6 Historic and Forecasted Market Size By Method
9.5.6.1 (Growth-Based Rapid Microbiology Testing
9.5.6.2 Cellular Component-Based Rapid Microbiology Testing
9.5.6.3 Nucleic Acid-Based Rapid Microbiology Testing
9.5.6.4 Viability-Based Rapid Microbiology Diagnostic Testing
9.5.6.5 Other Rapid Microbiology Testing Methods
9.5.7 Historic and Forecasted Market Size By End-User
9.5.7.1 (Laboratories and Hospitals
9.5.7.2 Food and Beverage Companies
9.5.7.3 Pharmaceutical and Biotechnology Companies
9.5.7.4 Contract Research Organizations
9.5.7.5 Other End-Users)
9.5.8 Historic and Forecast Market Size by Country
9.5.8.1 China
9.5.8.2 India
9.5.8.3 Japan
9.5.8.4 South Korea
9.5.8.5 Malaysia
9.5.8.6 Thailand
9.5.8.7 Vietnam
9.5.8.8 The Philippines
9.5.8.9 Australia
9.5.8.10 New Zealand
9.5.8.11 Rest of APAC
9.6. Middle East & Africa Ranitidine Market
9.6.1 Key Market Trends, Growth Factors and Opportunities
9.6.2 Top Key Companies
9.6.3 Historic and Forecasted Market Size by Segments
9.6.4 Historic and Forecasted Market Size By Product
9.6.4.1 (Instruments
9.6.4.2 Reagents and kits
9.6.4.3 Consumables
9.6.5 Historic and Forecasted Market Size By Application
9.6.5.1 (Clinical Disease Diagnosis
9.6.5.2 Food and Beverage Testing
9.6.5.3 Pharmaceutical and Biological Drug Testing
9.6.5.4 Environmental Testing
9.6.5.5 Cosmetics and Personal Care Products Testing
9.6.5.6 Research Applications
9.6.5.7 Other Applications
9.6.6 Historic and Forecasted Market Size By Method
9.6.6.1 (Growth-Based Rapid Microbiology Testing
9.6.6.2 Cellular Component-Based Rapid Microbiology Testing
9.6.6.3 Nucleic Acid-Based Rapid Microbiology Testing
9.6.6.4 Viability-Based Rapid Microbiology Diagnostic Testing
9.6.6.5 Other Rapid Microbiology Testing Methods
9.6.7 Historic and Forecasted Market Size By End-User
9.6.7.1 (Laboratories and Hospitals
9.6.7.2 Food and Beverage Companies
9.6.7.3 Pharmaceutical and Biotechnology Companies
9.6.7.4 Contract Research Organizations
9.6.7.5 Other End-Users)
9.6.8 Historic and Forecast Market Size by Country
9.6.8.1 Turkiye
9.6.8.2 Bahrain
9.6.8.3 Kuwait
9.6.8.4 Saudi Arabia
9.6.8.5 Qatar
9.6.8.6 UAE
9.6.8.7 Israel
9.6.8.8 South Africa
9.7. South America Ranitidine Market
9.7.1 Key Market Trends, Growth Factors and Opportunities
9.7.2 Top Key Companies
9.7.3 Historic and Forecasted Market Size by Segments
9.7.4 Historic and Forecasted Market Size By Product
9.7.4.1 (Instruments
9.7.4.2 Reagents and kits
9.7.4.3 Consumables
9.7.5 Historic and Forecasted Market Size By Application
9.7.5.1 (Clinical Disease Diagnosis
9.7.5.2 Food and Beverage Testing
9.7.5.3 Pharmaceutical and Biological Drug Testing
9.7.5.4 Environmental Testing
9.7.5.5 Cosmetics and Personal Care Products Testing
9.7.5.6 Research Applications
9.7.5.7 Other Applications
9.7.6 Historic and Forecasted Market Size By Method
9.7.6.1 (Growth-Based Rapid Microbiology Testing
9.7.6.2 Cellular Component-Based Rapid Microbiology Testing
9.7.6.3 Nucleic Acid-Based Rapid Microbiology Testing
9.7.6.4 Viability-Based Rapid Microbiology Diagnostic Testing
9.7.6.5 Other Rapid Microbiology Testing Methods
9.7.7 Historic and Forecasted Market Size By End-User
9.7.7.1 (Laboratories and Hospitals
9.7.7.2 Food and Beverage Companies
9.7.7.3 Pharmaceutical and Biotechnology Companies
9.7.7.4 Contract Research Organizations
9.7.7.5 Other End-Users)
9.7.8 Historic and Forecast Market Size by Country
9.7.8.1 Brazil
9.7.8.2 Argentina
9.7.8.3 Rest of SA
Chapter 10 Analyst Viewpoint and Conclusion
10.1 Recommendations and Concluding Analysis
10.2 Potential Market Strategies
Chapter 11 Research Methodology
11.1 Research Process
11.2 Primary Research
11.3 Secondary Research
|
Global Ranitidine Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 980 Million |
|
Forecast Period 2024-32 CAGR: |
3.8% |
Market Size in 2032: |
USD 1,370.89 Million |
|
|
By Indication |
|
|
|
By Population Type |
|
||
|
By Dosage Form |
|
||
|
By Dosage Strength |
|
||
|
By Mode of Purchase |
|
||
|
By End User |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
